StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
51
This year
3
Publishing Date
2024 - 02 - 15
1
2024 - 01 - 22
1
2024 - 01 - 09
1
2023 - 12 - 11
1
2023 - 10 - 04
1
2023 - 08 - 14
1
2023 - 08 - 03
1
2023 - 07 - 11
1
2023 - 06 - 16
1
2023 - 05 - 26
1
2023 - 03 - 07
1
2022 - 11 - 04
1
2022 - 10 - 05
1
2022 - 09 - 26
1
2022 - 07 - 27
1
2022 - 07 - 11
1
2022 - 07 - 04
1
2022 - 06 - 27
1
2022 - 06 - 24
1
2022 - 06 - 21
1
2022 - 06 - 20
1
2022 - 06 - 09
1
2022 - 05 - 26
1
2022 - 05 - 23
1
2022 - 05 - 19
1
2022 - 05 - 16
1
2022 - 04 - 12
1
2022 - 04 - 04
1
2022 - 03 - 30
1
2022 - 03 - 24
1
2022 - 03 - 15
1
2022 - 03 - 14
2
2022 - 02 - 24
1
2022 - 02 - 14
1
2021 - 12 - 02
1
2021 - 11 - 22
1
2021 - 11 - 19
1
2021 - 10 - 14
1
2021 - 10 - 11
1
2021 - 10 - 04
1
2021 - 09 - 27
1
2021 - 08 - 27
1
2021 - 08 - 24
1
2021 - 06 - 28
1
2021 - 06 - 07
1
2021 - 06 - 01
1
2021 - 05 - 26
1
2021 - 05 - 20
1
2021 - 03 - 12
1
2021 - 02 - 22
1
Sector
Health technology
51
Transportation and warehousing
1
Tags
Acquisition
87
Alliances
89
America
64
Antibody
65
Approval
97
Biopharma
103
Biotech
87
Biotechnology
120
Business
80
Cancer
215
Children
68
Clinical-trials-phase-ii
51
Clinical-trials-phase-iii
80
Collaboration
102
Companies
59
Conference
58
Covid
128
Covid-19
111
Diabetes
60
Disease
179
Drug
240
Dupixent
118
Earnings
96
Europe
92
Events
61
Fda
236
Financial
163
Financial results
72
Genetown
73
Global
356
Growing
56
Growth
325
Health
71
Insulin
54
Iot
56
Market
719
Money
70
N/a
2816
News
123
People
224
Pharm-country
54
Pharma
191
Pharmaceutical
143
Positive
103
Potential
67
Regulatory
58
Report
312
Research
265
Results
366
Sanofi
199
Spac
62
Study
86
Technology
68
Therapeutics
342
Therapy
113
Treatment
277
Trial
165
Update
91
Vaccine
258
Year
61
Entities
Abvc biopharma inc
6
Adamis pharmaceuticals corporation
5
Aldeyra therapeutics, inc.
9
Algernon pharmaceuticals inc.
6
Alzamend neuro inc
7
Amgen inc.
6
Amylyx pharmaceuticals, inc.
6
Anavex life sciences corp.
6
Annovis bio, inc.
7
Aptinyx inc.
6
Arcturus therapeutics holdings inc.
6
Arrowhead pharmaceuticals, inc.
17
Astrazeneca plc
7
Axcella health inc.
6
Beigene, ltd.
9
Biogen inc.
5
Biovie inc.
5
Bristol-myers squibb company
15
Can-fite biopharma ltd
7
Cardiff oncology, inc.
5
Clearside biomedical, inc.
7
Clene inc
7
Curis, inc.
6
Cybin inc
11
Diamedica therapeutics inc.
6
Dynavax technologies corporation
5
Edesa biotech, inc.
6
Eli lilly and company
18
First wave biopharma, inc.
9
Fortress biotech, inc.
7
Galecto, inc.
5
Gilead sciences, inc.
7
Gritstone oncology, inc.
5
Horizon therapeutics public limited company
7
I-mab
13
Ideaya biosciences, inc.
5
Immutep limited
10
Incyte corporation
6
Infinity pharmaceuticals, inc.
6
Johnson & johnson
54
Kintara therapeutics, inc.
7
Lineage cell therapeutics, inc.
7
Maia biotechnology, inc.
11
Mediwound ltd.
11
Merck & company, inc.
9
Moderna, inc.
8
Moleculin biotech, inc.
7
Mymd pharmaceuticals inc
6
Orange
9
Pds biotechnology corporation
6
Pfizer, inc.
9
Protagonist therapeutics, inc.
7
Redhill biopharma ltd.
10
Regenxbio inc.
7
Sanofi
51
Scholar rock holding corporation
6
Sorrento therapeutics, inc.
7
Takeda pharmaceutical company limited
10
Vertex pharmaceuticals incorporated
9
Virios therapeutics inc
6
Symbols
ACER
1
AGEN
1
ALNY
1
CFRX
1
IPHA
5
IPHYF
5
JNJ
4
MNKD
1
MRNA
1
NVO
1
OPT
1
REGN
1
RGLS
1
SKYE
1
SNY
51
SNYNF
42
Exchanges
Nasdaq
51
Nyse
5
Crawled Date
2024 - 02 - 15
1
2024 - 01 - 22
1
2024 - 01 - 09
1
2023 - 12 - 11
1
2023 - 10 - 04
1
2023 - 08 - 14
1
2023 - 08 - 03
1
2023 - 07 - 11
1
2023 - 06 - 16
1
2023 - 05 - 26
1
2023 - 03 - 07
1
2022 - 11 - 04
1
2022 - 10 - 05
1
2022 - 09 - 26
1
2022 - 07 - 27
1
2022 - 07 - 11
1
2022 - 07 - 04
1
2022 - 06 - 27
1
2022 - 06 - 24
1
2022 - 06 - 21
1
2022 - 06 - 20
1
2022 - 06 - 09
1
2022 - 05 - 26
1
2022 - 05 - 23
1
2022 - 05 - 19
1
2022 - 05 - 16
1
2022 - 04 - 12
1
2022 - 04 - 04
1
2022 - 03 - 30
1
2022 - 03 - 24
1
2022 - 03 - 15
1
2022 - 03 - 14
2
2022 - 02 - 24
1
2022 - 02 - 14
1
2021 - 12 - 02
1
2021 - 11 - 22
1
2021 - 11 - 19
1
2021 - 10 - 14
1
2021 - 10 - 11
1
2021 - 10 - 04
1
2021 - 09 - 27
1
2021 - 08 - 27
1
2021 - 08 - 24
1
2021 - 06 - 28
1
2021 - 06 - 07
1
2021 - 06 - 01
1
2021 - 05 - 26
1
2021 - 05 - 20
1
2021 - 03 - 12
1
2021 - 02 - 22
1
Crawled Time
05:00
4
06:00
2
07:00
1
08:00
2
09:00
1
10:00
2
12:00
5
12:30
1
13:00
8
13:30
1
14:00
4
14:20
2
15:00
6
15:30
1
16:00
4
17:00
4
18:00
1
20:00
1
22:00
1
Source
www.biospace.com
51
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Clinical-trials-phase-ii
entities :
Sanofi
save search
Sanofi Gets Phase II MS Win, Eyes $5B in Peak Annual Sales for Pipeline
Published:
2024-02-15
(Crawled : 17:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
2.49%
|
O:
1.16%
H:
1.48%
C:
0.89%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-0.33%
|
O:
1.86%
H:
0.0%
C:
0.0%
sales
pipeline
sanofi
6 Neuro Data Readouts to Watch in the First Half of 2024
Published:
2024-01-22
(Crawled : 07:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-8.68%
|
O:
1.71%
H:
0.0%
C:
-0.15%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.18%
|
O:
-0.21%
H:
0.0%
C:
0.0%
first
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published:
2024-01-09
(Crawled : 16:00)
- biospace.com/
SKYE
|
$16.16
-4.77%
-5.01%
110K
|
Transportation and Warehousing
|
617.36%
|
O:
-7.02%
H:
29.11%
C:
15.56%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.68%
|
O:
0.74%
H:
0.0%
C:
0.0%
obesity
disease
kidney
bioscience
clearance
trial
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
Published:
2023-12-11
(Crawled : 08:00)
- biospace.com/
IPHYF
|
$2.65
104.6%
300
|
Health Technology
|
11.81%
|
O:
9.45%
H:
0.0%
C:
-1.7%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-0.54%
|
O:
0.5%
H:
1.67%
C:
0.1%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-1.51%
|
O:
2.15%
H:
0.0%
C:
0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
|
-8.91%
|
O:
-1.16%
H:
0.39%
C:
-4.31%
sar4435
pharma
iph6101
cell
results
sanofi
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Published:
2023-10-04
(Crawled : 12:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-14.62%
|
O:
1.07%
H:
0.0%
C:
0.0%
MRNA
S
|
$101.44
-0.55%
-0.55%
2.6M
|
Health Technology
|
0.35%
|
O:
1.48%
H:
0.2%
C:
-0.33%
rna-1083
covid-19
vaccine
positive
influenza
Launch of Insilico’s Phase II Program Highlights Generative AI Momentum
Published:
2023-08-14
(Crawled : 05:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-14.15%
|
O:
0.04%
H:
0.0%
C:
0.0%
momentum
program
Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma
Published:
2023-08-03
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-10.05%
|
O:
-1.6%
H:
0.11%
C:
0.11%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-12.72%
|
O:
-3.79%
H:
0.0%
C:
0.0%
publication
therapeutics
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
Published:
2023-07-11
(Crawled : 06:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-12.4%
|
O:
-0.12%
H:
0.0%
C:
0.0%
iph6401
trial
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
Published:
2023-06-16
(Crawled : 10:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.3%
|
O:
2.42%
H:
0.0%
C:
0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
|
-27.91%
|
O:
1.84%
H:
6.63%
C:
4.82%
pharma
results
study
phase 2
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
Published:
2023-05-26
(Crawled : 09:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-11.8%
|
O:
0.5%
H:
1.67%
C:
1.67%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-14.31%
|
O:
-0.21%
H:
0.0%
C:
0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
|
-18.69%
|
O:
1.04%
H:
1.54%
C:
-0.51%
iph6101
pharma
cell
aml
sanofi
Merck Preps Potential First Oral PCSK9 Inhibitor for Phase III
Published:
2023-03-07
(Crawled : 14:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-4.65%
|
O:
0.65%
H:
0.0%
C:
0.0%
potential
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Published:
2022-11-04
(Crawled : 10:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
6.86%
|
O:
-0.02%
H:
0.43%
C:
0.43%
NVO
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
|
9.36%
|
O:
-0.25%
H:
0.11%
C:
-1.03%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
7.26%
|
O:
2.05%
H:
0.0%
C:
0.0%
IPHA
|
$2.48
5.53%
5.24%
9.4K
|
Health Technology
|
10.85%
|
O:
-4.27%
H:
8.9%
C:
6.93%
pharma
trial
results
platform
TrialSpark and Sanofi Ink Six-Drug Deal Targeting Areas with High Unmet Need (Updated)
Published:
2022-10-05
(Crawled : 22:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
14.58%
|
O:
-0.2%
H:
0.0%
C:
0.0%
deal
sanofi
FDA Action Alert: Amylyx's Moment of Truth and Dupixent Seeks another Nod
Published:
2022-09-26
(Crawled : 05:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
26.36%
|
O:
5.77%
H:
0.0%
C:
-2.27%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
18.58%
|
O:
-2.29%
H:
0.35%
C:
-0.67%
fda
dupixent
Editas’ Novel Sickle Cell Therapeutic Shows Early Promise
Published:
2022-07-27
(Crawled : 15:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-9.67%
|
O:
-0.24%
H:
0.0%
C:
0.0%
promise
Myrtelle's Investigational Canavan Disease Treatment Shows Early Promise
Published:
2022-07-11
(Crawled : 13:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.98%
|
O:
1.85%
H:
0.0%
C:
-0.15%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-9.23%
|
O:
0.49%
H:
0.0%
C:
0.0%
treatment
disease
promise
Innate's Cancer Therapeutics are Reaching New Clinical Heights
Published:
2022-07-04
(Crawled : 05:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
Email alert
Add to watchlist
therapeutics
cancer
COVID-19 Vaccine Leaders Make Progress on Omicron-Specific Boosters
Published:
2022-06-27
(Crawled : 14:20)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-11.29%
|
O:
4.15%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-13.2%
|
O:
0.53%
H:
0.0%
C:
0.0%
covid-19
vaccine
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Published:
2022-06-24
(Crawled : 13:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-4.19%
|
O:
8.01%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-10.17%
|
O:
3.49%
H:
0.0%
C:
0.0%
covid-19
vaccine
trial
results
topline
Can Olema Oncology Prevail Where Other SERDs have Recently Failed?
Published:
2022-06-21
(Crawled : 05:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-7.94%
|
O:
-3.92%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-7.59%
|
O:
1.4%
H:
0.0%
C:
0.0%
← Previous
1
2
3
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
News
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.